Astellas 'Xtandi' offers high efficacy with low side effects
By Whang, byung-woo | translator Hong, Ji Yeon
25.01.21 05:38:39
°¡³ª´Ù¶ó
0
Benefits observed in patients prescribed Extandi align with those in the ARCHES Phase 3 study
Emphasizes the role of regional hospitals in treating prostate cancer, prevalent in older age
As more treatment options are covered by reimbursement, concerns about 'how' best to treat prostate cancer are increasing.
Given the increasing number of prostate cancer patients increases each year, it is important to discuss which options to provide based on the patient's condition.
¡ãDr. Hong Koo Ha, Professor in the Department of Urology at Pusan National University Hospital
The specialist in the field, Dr. Hong Koo Ha, Professor in the Department of Urology at Pusan National University Hospital, emphasizes that there must be discussions about patient-customized treatment. The incidence of prostate cancer is rising among men diagnosed with cancer. The increase in diagnosis is attributed to factors such as aging, westernized dietary habits, and more frequent PSA (
Whang, byung-woo(tuai@dailypharm.com)
If you want to see the full article, please JOIN US (click)